Confluence Life Sciences, Inc., founded in 2010, is making strides in the biotechnology sector with its emphasis on developing innovative kinase inhibitors for human and animal health care. The company's slogan, "Pioneering the future of kinase inhibitors through innovative drug design and strategic collaborations in human and animal health care," encapsulates its mission to push the boundaries of conventional drug discovery approaches.
Specializing in rational drug design, CLS targets essential signal transduction enzymes linked to cancer and chronic inflammation. By focusing on novel binding sites of challenging kinase targets, CLS seeks to innovate beyond traditional pharmaceuticals. The company's success is reinforced by its team of top-tier experts and strategic partnerships.
While headquartered details are unspecified, CLS's most recent fundraising milestone was a $4.83M Venture Round investment on April 20, 2016. This financial backing underpins its continuous pipeline strategy in discovery, development, and partnerships.
